FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Zawel Leigh						2. Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. [ CGEM ]									all app Direc Office	tor 10 er (give title O		10% O	wner
(Last) (First) (Middle) C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 520						3. Date of Earliest Transaction (Month/Day/Year) 08/09/2021								See Remarks					
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) 08/11/2021									6. Indiv Line) X	·				
		Tab	le I - N	on-Deriva	tive S	Secu	rities	Acc	uired	l, Dis	sposed of	, or B	enefi	cially	Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			4 and 5) Securi Benefi Owned		ties cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D)	Price	е	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 08/09/2					021	21			S <sup>(1)</sup>		19,504	D	\$26	\$26.52(2)		130,256		D	
Common Stock 08/09/2					021			S <sup>(1)</sup>		1,700	D	\$27	\$27.11 <sup>(3)</sup>		128,556		D		
Common Stock 08/10/20					021				S <sup>(1)</sup>		1,906	D	\$2	\$26.5(4)		126,650		D	
Common Stock 08/10/20					021				S <sup>(1)</sup>		3,191	D	\$27	\$27.34 <sup>(5)</sup>		123,459		D	
Common Stock 08/10/20					)21				S <sup>(1)</sup>		1,817	D	\$28	\$28.49(6)		121,642		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security		Execur) if any			action (Instr.			6. Date Exer Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)  Amour or Numbe of		nt er		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

- 1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
- 2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$25.98 to \$26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$26.98 to \$27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote
- 4. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$25.95 to \$26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 5. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$26.95 to \$27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote
- 6. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$28.07 to \$28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Chief Scientific Officer, Small Molecules This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.

> /s/ Jeffrey Trigilio, Attorneyin-Fact

08/26/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.